TME Pharma N.V.: TME Pharma Announces Publication of ASCO 2023 Abstract Disclosing New Biomarker Data From NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma

Abstract highlights biomarker with ability to predict clinical responses of glioblastoma patients to NOX-A12-based therapies Patients with high biomarker score show superior clinical efficacy

Related Keywords

France ,Paris ,France General ,Mannheim ,Baden Wüberg ,Germany ,Spain ,Chicago ,Illinois ,United States ,American ,Pharmanv Euronext ,Aram Mangasarian ,Arthur Rouill ,Gewinn Nur ,Franka Giordano ,Merck Keytruda ,Guillaume Van Renterghem ,University Medical Center Mannheim ,Twitter ,Department Of Radiation Oncology ,American Society Of Clinical Oncology ,Merck Sharp Dohme Corp ,Euronext Growth Paris ,American Society ,Clinical Oncology ,Saturday June ,Radiation Oncology ,Poster Session ,Central Nervous System Tumors ,Merck Sharp Dohme ,Media Relations ,Pharma ,Nnounces ,Publication ,Disco ,023 ,Abstract ,Disclosing ,Biomarker ,Data ,Rom ,Gloria ,Hase ,Trial ,Glioblastoma ,